Shah Capital Management has withdrawn a proxy campaign against the re-election of directors at vaccines firm Novavax in the wake of its $1.2 billion alliance with Sanofi.
Shah Capital has stepped up its campaign for change at vaccine producer Novavax, lobbying against the re-election of three directors and executive pay packages in a letter
Shah Capital has fired a broadside at the management team of Novavax, seeking a change in leadership at the vaccine company and the appointment of two handpicked directors
As the financial markets have been roiled by inflation and a minor banking crisis, the pharma industry experienced a period where M&A largely disappeared and investment into biotechs dr
Bayer chief executive Werner Baumann has been under fire from investors since he spearheaded the acquisition of agrochemical company Monsanto for $63 billion, exposing the group to multibil
Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone mineral density that could undermine its ability to compete in t
Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.
